A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell Cancer
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 13 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 02 Aug 2022 Planned End Date changed from 1 Jun 2022 to 31 Dec 2022.